The failure of OzemPic drugs in the treatment of Parkinson’s disease in the trial
The idea was very confusing. Medicines in the GLP-1 category, which include Wegovy and OzemPIC, have proven a miracle in the treatment of weight loss and other diseases. Some researchers expressed their hope that medications can also help in some of the most difficult diseases to be treated – those in the brain, such as Parkinson’s.
But now, at least for Parkinson, hope seems to be dependent. A strict study showed that Parkinson’s patients were randomly appointed to take Xinaidide, a relative of Ozmik, at all benefit or slowdown in the course of the degenerative disease after 96 weeks.
There was no effect on the patient’s symptoms, there is no effect on brain tests, and there is no sub -group that showed any benefit. Regardless of how researchers cut data, the results were the same.
the studyAnd published on Tuesday in Lancet, it is bad news for half a million Americans who were diagnosed with Parkinson’s disease. Symptoms include tremors, hardness and difficulty balance. Patients may also develop dementia. Treatments, including medications and deep brain stimulation, can help symptoms. But no treatment has been proven to slow the disease.
“It is very disappointing,” said Dr. Thomas Volini of the University of London, which led the trial. “We expected to come and get a positive result.”
Parkinson’s experts shared his feelings.
Dr. Michael S. said. Okon, Parkinson’s pathology expert at the University of Florida and the National Medical Adviser to the Parkinson Foundation: “This is a realistic moment.” “This is a truly good study and has appeared empty -handed.”
Discovery may have effects on researchers who ask whether the newer GLP-1 medications can help slow Alzheimer’s course or may prevent disease.
The new study included 194 people suffering from Parkinson’s disease treated in six research hospitals in the United Kingdom, and patients were randomly assigned to inject themselves once a week for 96 weeks with Xenatid, a type 2 treatment that was made by Astrazneca and sold under the name Brand bytta, or with a placebo. The trial was funded by the National Institute for Health and Care Research in Britain with the support of alternatives from the Parkinson’s Charitable Treatment Institute and the Van Andal Institute.
The drug is in the same category OzemPIC and Wegovy, and the same, reduces blood sugar levels. All of the so-called GLP-1 receptors, which are usually called GLP-1S. EXENATIDE is not strong in provoking weight loss like the latest medications, but experts say there is no reason to believe that the most modern drugs will work differently in brain disease studies.
The researchers said that the results are especially disappointing because there are suggestions that the GLP-1 may help Parkinson’s patients.
GLP-1 Nerve cells Of the damage to laboratory studies and In study With mice gave a brain injury like this in Parkinson’s disease.
It seems that the results may also apply to patients.
“People began researching the claims databases,” Dr. Okon said, explaining that the researchers have examined large databases that explain the drugs that people took and their diagnosis. The researchers asked whether the patients who took the GLP-1 might be less likely to get Parkinson’s or, if they have, will have more slowly advanced disease.
The results were promising.
They looked In epidemiological studies. They found that people with diabetes who took the GLP-1 were less likely to Parkinson.
Then I suggested two small studies Which – which Exhannel may slow up progress Of some Parkinson’s symptoms for a year.
Continue progress hints, a larger but still primary study, Posted last year In the New England Medicine Journal, I found that the GLP-1 is no longer on the market-Lixisenatide-it seems a bit slow in the disease for a year.
At the time, Dr. Okon said that the result was “reports on the edges of the disease modification.”
“What we did last year was a year -old experience and a small sign,” said Dr. David Standard, Parkinson’s researcher at Alabama University in Birmingham. “What will happen if you go longer? Well, this is longer and there is not much here.”
Dr. Standett said that the problem of the GLP-1 study in Parkinson’s disease is that what Exhainid is supposed to do in the brain is unclear.
“I will not do another study like this unless I learn what is the goal,” said Dr. Standett. “What is the biochemistry you are trying to change in the brain? How do these medications work, however?”